|
|
Article: Lundbeck to market Neurim insomnia treatment: The treatment, based on prolonged release Melatonin, is approved in Europe.
- Article from:
- Globes
- Article date:
- September 25, 2007
|
Copyright informationCOPYRIGHT 2007 Globes. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Byline: Gali Weinreb
Sep. 25--Neurim Pharmaceuticals Ltd. has granted Danish pharmaceutical company H. Lundbeck A/S (KFX:LUN) a license for exclusive rights to market its Circadin treatment of primary insomnia in the majority of European markets, including the UK, Germany, France, Spain, and Poland. Lundbeck was also granted an exclusive option to evaluate commercialization in markets outside of Europe. Lundbeck said that it expected to launch Circadin in the first markets during 2008.
Neurim declined to disclose the size of the deal, but said that it "receives an upfront payment and a share of revenue. Neurim is responsible for manufacturing."
A rough estimate on ...
Related newspaper, magazine, and journal articles:
|